Published • loading... • Updated
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
Deep Track said the stake fits its concentrated healthcare strategy as Alumis advances a TYK2 inhibitor with 68.0% Phase 3 psoriasis response rates.
Summary by The Motley Fool
1 Articles
1 Articles
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
Key PointsDeep Track Capital bought 6,772,595 shares of Alumis last quarter; the estimated transaction value was $169.31 million (based on average prices).Meanwhile, the quarter-end position value changed by $149.20 million, reflecting the new stake.The transaction represented a 2.76% increase relative to Deep Track Capital’s 13F reportable assets under management (AUM).10 stocks we like better than Alumis › On May 15, 2026, Deep Track Capital d…
·Alexandria, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
